Efficacy, safety of nintedanib in Asian patients with IPF sustained in long term
07 Apr 2020
byStephen Padilla
Treatment with nintedanib slows disease progression of idiopathic pulmonary fibrosis (IPF) in Asian patients, and this beneficial effect persists over the long term, with acceptable safety and tolerability profile, suggest the results from a subgroup analysis of data from INPULSIS-ON, the open-label extension of the INPULSIS trials.
